Adma Biologics: Q3 Earnings Snapshot
Adma Biologics (ADMA) reported Q3 profit of $49.9M, or 22 cents per share, with revenue of $141.1M. The company expects full-year revenue of $530M. Shares have fallen 43% YTD and 28% over the past year, closing at $10.48 on Wednesday.
How this was made
The 30-second read
Why it matters
The earnings release adds fresh financial data for a micro‑cap biotech, offering a modest trading signal.
Market read
New earnings data for ADMA provides a limited but actionable insight for traders focused on biotech micro‑caps.
What to watch
Guidance of $530M FY revenue suggests growth potential if new products launch.
Background
Adma Biologics is an infectious‑disease drug developer listed on Nasdaq (ADMA). The article is an automated earnings snapshot.
Ticker impact
Q3 earnings release reporting $49.9M profit, $141.1M revenue and FY guidance of $530M.
likely pressure as the market may price in slower growth despite profit beat
First report of earnings for a micro‑cap; numbers are new but scale is limited, so impact is modest.
Market effects
Provides a data point for the infectious‑disease biotech sector, but limited broader impact.
U.S. biotech market sees a small addition of earnings data; no regional shift.
Low global relevance; company is a niche player.
Counterpoint
Despite weak YTD performance, the profit beat could signal a turnaround if pipeline advances.
Key entities
- companyAdma Biologics Inc.
Infectious‑disease drug developer reporting Q3 results.
